LLY Price Prediction Next Week
Stock Price Prediction for Eli Lilly (LLY)
News and Event Impact:
Positive Clinical Trial Results: Eli Lilly recently announced successful Phase 3 results for baricitinib in treating adolescents with severe alopecia areata, demonstrating significant hair regrowth. This underscores the company's strong pipeline and potential for future growth.
Weight-Loss Drug Market Expansion: The rapid growth of the weight-loss drug market, with LLY's Zepbound as a key competitor, positions the company well in a high-demand sector. Analysts project significant revenue growth, with LLY's obesity drugs expected to contribute substantially to its 2025 sales.
Accelerated Drug Development: LLY has expedited the release of data for its new weight-loss drug candidate, retatrutide, which could potentially outperform current market leaders. Early reports suggest higher efficacy compared to existing treatments.
Technical Analysis:
- Current Price: LLY closed at $869.58 on March 7, 2025.
- RSI (14): 49.18, indicating the stock is not in oversold territory.
- MACD: The MACD line is above the signal line, suggesting bullish momentum, but the gap is narrowing, which could indicate a near-term pullback.
- Fibonacci Levels:
- Pivot Point: $901.57
- Resistance Levels: $929.92 (R1), $947.44 (R2)
- Support Levels: $873.21 (S1), $855.69 (S2)
Price Prediction and Recommendation:
Based on the combination of positive news flow and technical analysis, LLY is expected to experience a slight pullback in the short term due to profit-taking. However, the overall trend remains bullish, driven by strong fundamentals and positive catalysts.
Predicted Price Range for Next Trading Week: $860 - $900
Recommendation: BUY on dips near the lower end of the range, targeting the upper resistance level of $900.
LLY Similar Chart Price Prediction
The price of LLY is predicted to go up 7.32%, based on the high correlation periods with CRL. The similarity of these two price pattern on the periods is 97.56%.
LLY
CRL
Up: 7.32%Similarity: 97.56%
LLY Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
LLY Price Forecast($)
Potential Return(%)
2025
787.140
0.660
2026
1,200.000
30.350
2027
1,200.000
30.350
2028
1,400.000
52.070
2029
1,500.000
62.930
2030
1,500.000
62.930
What is LLY stock price prediction 2025 ?
What is LLY stock price prediction 2026 ?
What is LLY stock price prediction 2027 ?
What is LLY stock price prediction 2028 ?
What is LLY stock price prediction 2029 ?
What is LLY stock price prediction 2030 ?
LLY Revenue Forecast
LLY EPS Forecast
LLY FAQs
What is LLY revenue forecast for next quarter？
What is LLY eps forecast for next quarter？
LLY VS S&P500
Lilly's strong leadership in weight-loss drugs should drive industry-leading growth with approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.
Lilly's cancer drug Verzenio reported strong data in early-stage breast cancer, opening up the strong potential in this multi-billion-dollar market.
Lilly is developing a new Alzheimer's drug (donanemab) that could become a major blockbuster, especially because the FDA appears to have a lower threshold for approval for this disease.
LLY Analyst's Forecast
Srikripa Devarakonda
Truist Securities
Strong Buy
2025-02-03
Price Target
$1,029 → $1,038
Upside
+28.08%
Truist analyst Srikripa Devarakonda says that in early questioning today, Robert Francis Kennedy Jr. reiterated that he does not want to "take away vaccines," claiming that he is not anti-vaccine nor anti-industry but is simply an advocate of safety. This is a contradiction to his legacy of anti-vaccine involvement, the analyst tells investors in a research note. "Given early comments which seem more muted and given his history, we question if the verbiage during hearing could ultimately be contradicted later if he is sworn into office," contends Truist. The firm expects questioning on vaccines, which affects Pfizer (PFE) and Merck (MRK), and on chronic illness, which affects Eli Lilly (LLY) and Amgen (AMGN). RFK Jr. has been outspoken against vaccines but "his bark may be bigger than his bite," according to Truist. It awaits to see more unfold.
Tim Anderson
B of A Securities
Strong Buy
2024-12-10
Price Target
$997
Upside
+24.69%
Alexandria Hammond
Wolfe Research
Buy
2024-11-15
Price Target
$1,000
Upside
+34.01%
